A strategy of breaking
The choice of daily pathologies
In response to the constraints weighing on the health industries, the directors of INNOTHERA decided to concentrate on daily pathologies.
These diseases that are often symptomatic, chronic, but without major or lethal risks do not lend themselves to sophisticated, costly treatments that involve significant side effects. This segment of the market is the one most often neglected by the research departments of the major laboratories.
The treatment of these daily pathologies requires products whose effectiveness
is recognized, and whose product licensing dossiers are kept up
to date. It also requires that the company be able to rely on galenic research
associated with analytic and microbiological development of high quality.
INNOTHERA therefore decided to embark on a program of pharmaceutical development
aimed at filling out its portfolio of products, emphasizing galenic improvement.
Mastery over galenic development
Since therapeutic habits and practices vary from one country to another, galenic development requires adapting to local needs. For each country involved, each medicine must be presented in the form that is most suitable in terms of habits of consumption, ease of use, and prevailing climatic conditions. The same medicine can therefore be marketed in multiple forms (tablets, capsules, soluble powder, etc.)
This ability to provide its pharmaceutical products in multiple galenic
forms (except for injectable solutions) and in small series is today one of INNOTHERA’s
strong points. Galenic research can be seen as a key to the success of
the Group’s development in the area of medicines.
Supplying the markets is a long and complex process. In addition to the need for
specific packaging, translations of use instructions, and stability studies, there
are regulatory requirements regarding expiration dates in each country, which
significantly increases the complexity of industrial planning.
Its experience in galenic research, combine with its ability to understand the diversity of the markets, have given Innothera a high degree of mastery over all industrial processes. As a result, the Group has been able to survive the propagation of generic products manufactured in emerging countries by insisting on the quality of its products, by successfully exporting the guarantee of an officially stamped European product, and by offering the most appropriate galenic formulations.
Always deeply involved in the treatment of venous disease, in particular with its Diovenor, but also with the program of research on molecules launched in 1989 (a program which until 2000 involved more than 100 researchers), the Laboratory decided in 1993 to develop the field of venous compression, an internationally recognized treatment of reference for venous disease.
The goal, at the price of very ambitious investment, is to become the leader on this market – first in France and then at the international level. This new activity was a means of anticipating any decline in the medicines market in France. Such a decline effectively took place beginning in 1999.
